Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Networking & Security
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Duquesne University Of The Holy Spirit has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is highly decentralized, with 8 distinct examiners assigned to the 8 pending actions. This means every single pending matter is being reviewed by a different individual. The busiest examiner, JHAVERI, JAYESH M, is responsible for 1 pending action, which is the same count as every other examiner involved.
Furthermore, these 8 actions are spread across 7 distinct art units. This indicates that the university's research is technically diverse, touching on nearly as many specialized USPTO units as there are pending cases. For a practitioner, this structure requires managing 8 separate prosecution tracks with almost no overlap in examiner or art unit expertise. Each of the 8 pending office actions must be approached as a unique case, as the data shows no concentration that would allow for a unified strategy across multiple filings. The 7 distinct art units suggest that the biotechnology filings cover a wide array of pharmaceutical or biological sub-fields.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 4 (50%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JHAVERI, JAYESH M | 1 | 82.9% | +30.8% |
| PACKARD, BENJAMIN J | 1 | 66.7% | +15.6% |
| PONTIUS, JAMES M | 1 | 78.9% | +9.6% |
| ZOUBAIR, NOURA | 1 | 72.8% | +62.3% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.3% |
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| PERREIRA, MELISSA JEAN | 1 | 52.0% | +25.8% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18964281 | Coral Reef Monitoring Device and Method | PONTIUS, JAMES M | 87d overdue |
| 19190955 | Automatic Extraction of Log-In Security Questions and Answers from Personal Devices | JHAVERI, JAYESH M | — |
| 18971892 | Ionic Liquid-Incorporated Lipid Nanoparticles | PACKARD, BENJAMIN J | — |
| 18638213 | Design, Synthesis, and Structure-Activity Relationships of Substituted Pyrido[3,2-d]Pyrimidines as Microtubule Targeting Agents and Anti-Cancer Agents | HOWELL, THEODORE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17451521 | MICRO RNA INTERACTIONS AS THERAPEUTIC TARGETS FOR COVID-19 AND OTHER VIRAL INFECTIONS | VYAS, KEYUR ANILKUMAR | 113d overdue |
| 17605846 | Implantable Device Coated by a Self-Assembled Monolayer and Therapeutic Agent | PERREIRA, MELISSA JEAN | 91d overdue |
| 18899703 | Personal Security Method to Establish and Preserve Pseudonymity of a Writer | ZOUBAIR, NOURA | 79d overdue |
| 19190955 | Automatic Extraction of Log-In Security Questions and Answers from Personal Devices | JHAVERI, JAYESH M | — |
| 18971892 | Ionic Liquid-Incorporated Lipid Nanoparticles | PACKARD, BENJAMIN J | — |
| 18638213 | Design, Synthesis, and Structure-Activity Relationships of Substituted Pyrido[3,2-d]Pyrimidines as Microtubule Targeting Agents and Anti-Cancer Agents | HOWELL, THEODORE R | — |
| 18227026 | Mitochondria-Enriched Extracellular Vesicles | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 2433 | 1 |
| 2488 | 1 |
| 2434 | 1 |
| 1628 | 1 |
| 1612 | 1 |
| 1618 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19190955 | Automatic Extraction of Log-In Security Questions and Answers from Personal Devices | JHAVERI, JAYESH M | 2433 | §101§103§112 | Non-Final OA | — | Pending | Apr 28, 2025 |
| 18971892 | Ionic Liquid-Incorporated Lipid Nanoparticles | PACKARD, BENJAMIN J | — | §101§102§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18964281 | Coral Reef Monitoring Device and Method | PONTIUS, JAMES M | 2488 | §103§112 | Non-Final OA | 87d overdue | Pending | Nov 29, 2024 |
| 18899703 | Personal Security Method to Establish and Preserve Pseudonymity of a Writer | ZOUBAIR, NOURA | 2434 | §103 | Non-Final OA | 79d overdue | Pending | Sep 27, 2024 |
| 18638213 | Design, Synthesis, and Structure-Activity Relationships of Substituted Pyrido[3,2-d]Pyrimidines as Microtubule Targeting Agents and Anti-Cancer Agents | HOWELL, THEODORE R | 1628 | §103§112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18227026 | Mitochondria-Enriched Extracellular Vesicles | RONEY, CELESTE A | 1612 | §103 | Final Rejection | — | Pending | Jul 27, 2023 |
| 17605846 | Implantable Device Coated by a Self-Assembled Monolayer and Therapeutic Agent | PERREIRA, MELISSA JEAN | 1618 | §103 | Non-Final OA | 91d overdue | Pending | Oct 22, 2021 |
| 17451521 | MICRO RNA INTERACTIONS AS THERAPEUTIC TARGETS FOR COVID-19 AND OTHER VIRAL INFECTIONS | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 113d overdue | Pending | Oct 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial